TW202204348A - Ｃｈｋ１抑制劑之合成方法 - Google Patents

Ｃｈｋ１抑制劑之合成方法 Download PDF

Info

Publication number
TW202204348A
TW202204348A TW110111391A TW110111391A TW202204348A TW 202204348 A TW202204348 A TW 202204348A TW 110111391 A TW110111391 A TW 110111391A TW 110111391 A TW110111391 A TW 110111391A TW 202204348 A TW202204348 A TW 202204348A
Authority
TW
Taiwan
Prior art keywords
compound
mol
pharmaceutical composition
impurities
formula
Prior art date
Application number
TW110111391A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 施瓦貝
思深 賀
大連 趙
羅斯 米勒
瑞奇 杜麗娜
麥可 修摩拉
史蒂芬 戈特斯林
Original Assignee
美商西爾拉癌症醫學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西爾拉癌症醫學公司 filed Critical 美商西爾拉癌症醫學公司
Publication of TW202204348A publication Critical patent/TW202204348A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110111391A 2020-04-07 2021-03-29 Ｃｈｋ１抑制劑之合成方法 TW202204348A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006305P 2020-04-07 2020-04-07
US63/006,305 2020-04-07

Publications (1)

Publication Number Publication Date
TW202204348A true TW202204348A (zh) 2022-02-01

Family

ID=78024095

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110111391A TW202204348A (zh) 2020-04-07 2021-03-29 Ｃｈｋ１抑制劑之合成方法

Country Status (8)

Country Link
US (1) US12606550B2 (https=)
EP (1) EP4132922A4 (https=)
JP (1) JP2023523165A (https=)
CN (2) CN115443271A (https=)
BR (1) BR112022020278A2 (https=)
CA (1) CA3174222A1 (https=)
TW (1) TW202204348A (https=)
WO (1) WO2021207210A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
ATE369854T1 (de) 2001-10-19 2007-09-15 Ortho Mcneil Pharm Inc 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
EP1501514B1 (en) 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2005011597A2 (en) 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
JP4845736B2 (ja) 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US7691866B2 (en) 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
CN1243033C (zh) 2004-07-15 2006-02-22 合肥工业大学 一种通过内增韧制备薄膜级聚l－乳酸共聚物的方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2604284A1 (en) 2005-04-28 2006-11-02 Supergen, Inc. Protein kinase inhibitors
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP5052518B2 (ja) 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
EP2727909A1 (en) 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9000027B2 (en) 2008-02-04 2015-04-07 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8865726B2 (en) * 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
WO2013103836A2 (en) 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
ES2624307T3 (es) 2012-05-15 2017-07-13 Cancer Research Technology Ltd 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
CN102675858A (zh) 2012-05-22 2012-09-19 同济大学 一种具有形状记忆功能可降解泪管栓塞的制备方法
GB201316526D0 (en) 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
WO2015176033A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3347026A4 (en) 2015-09-09 2019-05-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
JP7273791B2 (ja) 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
CA3065803A1 (en) 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3092079A1 (en) 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors
CA3135165A1 (en) 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
MX2021013905A (es) 2019-05-14 2022-05-18 Sierra Oncology Inc Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法

Also Published As

Publication number Publication date
CN115443271A (zh) 2022-12-06
EP4132922A1 (en) 2023-02-15
WO2021207210A1 (en) 2021-10-14
CN120441567A (zh) 2025-08-08
US20230150994A1 (en) 2023-05-18
BR112022020278A2 (pt) 2022-12-06
JP2023523165A (ja) 2023-06-02
CA3174222A1 (en) 2021-10-14
EP4132922A4 (en) 2024-07-03
US12606550B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
CN111848614B (zh) 吡啶酮衍生物及抗流感病毒药物组合物
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
KR20220012248A (ko) 퀴나졸린 화합물 및 이의 의약품에서의 응용
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
JP7797486B2 (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
JP7774312B2 (ja) 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
KR20180005248A (ko) 복소환형 화합물의 합성
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
KR102799653B1 (ko) 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
EP3310772A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
TWI850492B (zh) 腺苷受體拮抗劑化合物
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
JP2025142218A (ja) バルベナジンの合成のための方法
TW202204348A (zh) Ｃｈｋ１抑制劑之合成方法
KR20150068960A (ko) 치환된 카바메이트 화합물 및 일시적 수용체 전위(trp) 채널 길항제로서의 이의 용도
US9078899B2 (en) Pyrazolyl-based carboxamides II
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3，4-二氢-1，4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
JP2025530793A (ja) Ｅｇｆｒ阻害剤及びその使用
US8815870B2 (en) 4-(2-(6-substituted-hexylidene) hydrazinyl)benzonitrile and preparation thereof
CN117222648B (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
Kawtharani et al. Direct Access to New Gem-Difluorinated Pyrido [1, 2-a] Pyrimidine-2-one Systems
HK40085073A (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
JP2025514712A (ja) ブロモドメインに対して活性な化合物
CN119019402A (zh) 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途
CN104098506A (zh) 一类苯并[c]咔唑酰胺化合物的制备方法及用途